Milestone Scientific Inc. (MLSS) Q2 2024 Earnings Call Transcript Summary
Milestone Scientific Inc. (MLSS) Q2 2024 Earnings Call Transcript Summary
Gross profit for Q2 2024 was $1.4 million, representing 76% of revenue, an improvement from 65% in Q2 2023.The following is a summary of the Milestone Scientific Inc. (MLSS) Q2 2024 Earnings Call Transcript:
以下是Milestone Scientific Inc.(MLSS) Q2 2024 業績會簡報:
Financial Performance:
金融業績：
Milestone Scientific reported Q2 2024 revenues of approximately $1.9 million, a decrease from $2.9 million in Q2 2023.
The U.S. e-commerce revenue for Q2 2024 was $1.3 million, up from $1.2 million in Q2 2023.
Gross profit for Q2 2024 was $1.4 million, representing 76% of revenue, an improvement from 65% in Q2 2023.
Net income for Q2 2024 was approximately $0.2 million, a positive shift from a loss of $1.3 million in Q2 2023.
Milestone Scientific報告Q2 2024營業收入約爲$190萬，相比Q2 2023的$290萬下降。
Q2 2024美國電子商務收入爲$130萬，較Q2 2023的$120萬增長。
Q2 2024毛利潤爲$140萬，佔營業收入的76％，相較於Q2 2023的65％有所改善。
Q2 2024淨利潤約爲$20萬，相較於Q2 2023的$130萬虧損有所改善。
Business Progress:
業務進展：
Successfully secured Medicare Part B physician payment rate assignment for CompuFlo Epidural System across multiple JMAC regions, marking a significant commercial milestone.
Launched a strategic partnership with Axial Biologics to enhance commercial penetration and adoption of the CompuFlo system in key states.
Achieved regulatory approval in Brazil to market the CompuFlo Epidural System, enhancing global market presence.
Focused on e-commerce platform enhancement in the Dental division to improve customer interaction and sales.
成功在多個JMAC地區獲得了CompuFlo Epidural System的醫療保險第B部分醫師支付價格，標誌着一個重要的商業里程碑。
與Axial Biologics建立了戰略合作伙伴關係，以提高CompuFlo系統在關鍵州的商業滲透和採用率。
獲得了在巴西市場推廣CompuFlo Epidural System的監管批准，增強了全球市場地位。
專注於改善牙科部門的電子商務平台以提高客戶互動和銷售。
Opportunities:
機會：
Anticipates ongoing revenue opportunities from gradual deployment of the CompuFlo epidural system under the new Medicare reimbursement plan.
Potential expansion in the federal and other government sectors pending Federal Supply Schedule (FSS) approval.
Growth prospects in Brazil and other Latin American markets following regulatory approval.
預計在新的醫保報銷計劃下逐步推廣CompuFlo硬膜外麻醉系統，將有持續的收入機會。
在聯邦供應時間表（FSS）獲批後，存在在聯邦和其他政府部門擴大的可能性。
在獲得監管批准後，巴西和其他拉丁美洲市場具有增長前景。
Risks:
風險：
Revenue challenges due to unresolved issues with freight forwarders, impacting international sales.
由於與貨運代理的未解決問題，影響國際銷售，收入面臨挑戰。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。